Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials-Reference-Cited by-同舟云学术

Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials

Published:2020-11 Issue:6 Volume:46 Page:427-441
ISSN:1262-3636
Container-title:Diabetes & Metabolism
language:en
Short-container-title:Diabetes & Metabolism

Author:

Mantovani A.^ORCID,Byrne C.D.,Scorletti E.,Mantzoros C.S.,Targher G.^ORCID

Publisher

Elsevier BV

Subject

Endocrinology,General Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference52 articles.

1. Epidemiological modifiers of non-alcoholic fatty liver disease: focus on high-risk groups;Lonardo;Dig Liver Dis,2015

2. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis;Younossi;J Hepatol,2019

3. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis;Ballestri;J Gastroenterol Hepatol,2016

4. Nonalcoholic fatty liver disease and risk of incident type 2 diabetes mellitus: a meta-analysis;Mantovani;Diab Care,2018

5. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases;Chalasani;Hepatology,2018

Cited by 91 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chrysin-loaded calixarene-cyclodextrin ternary drug delivery system inhibits TGF-β and galectin-1 mediated pathways in diabetic liver fibrosis;Biochemical Pharmacology;2024-11

2. Tissue-specific activation of insulin signaling as a potential target for obesity-related metabolic disorders;Pharmacology & Therapeutics;2024-10

3. Role of oral hypoglycaemic drugs in preventing complication in non-alcoholic fatty liver disease with type 2 diabetes mellitus;Journal of the Pakistan Medical Association;2024-08-23

4. Non-alcoholic fatty liver disease in type 2 diabetes: Emerging evidence of benefit of peroxisome proliferator-activated receptors agonists and incretin-based therapies;World Journal of Methodology;2024-06-20

5. Changes in Transient Elastography with Glucagon-Like Peptide-1 Receptor Agonist Use in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Real-World Retrospective Analysis;Metabolic Syndrome and Related Disorders;2024-06-13